Nanoform Partners with Revio Therapeutics
Nanoform Finland Plc announced a partnership with Revio Therapeutics to co-develop and commercialize GLIORA.
- GLIORA is a nano-formulated combination of olaparib and temozolomide.
- It will be administered locally as a long-acting, thermo-responsive hydrogel.
- The treatment targets high-grade glioma, a fast-growing and aggressive type of brain tumor.
GLIORA combines olaparib (Lynparza) and temozolomide (Temodar) for brain tumor treatment.
Nanoform Finland Plc is a medicine performance-enhancing company.
Author's summary: Nanoform partners with Revio Therapeutics for glioma treatment.